Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX

Amova Asset Management Americas Inc. decreased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 8.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,181,146 shares of the company’s stock after selling 109,408 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Nurix Therapeutics were worth $18,284,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Nurix Therapeutics by 32.5% in the fourth quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after buying an additional 1,460,736 shares during the period. General Atlantic L.P. purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $92,899,000. Morgan Stanley increased its holdings in Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after acquiring an additional 2,620,323 shares in the last quarter. Vestal Point Capital LP raised its stake in Nurix Therapeutics by 35.0% during the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock worth $88,969,000 after acquiring an additional 1,215,000 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in Nurix Therapeutics by 20.0% during the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after purchasing an additional 776,431 shares in the last quarter.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $22.71 on Tuesday. The firm has a market capitalization of $2.36 billion, a PE ratio of -6.58 and a beta of 1.80. The business has a 50 day simple moving average of $19.22 and a two-hundred day simple moving average of $17.52. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $25.08.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Equities research analysts expect that Nurix Therapeutics, Inc. will post -2.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on NRIX shares. Oppenheimer initiated coverage on Nurix Therapeutics in a research note on Monday, June 29th. They issued an “outperform” rating and a $28.00 price objective for the company. Wells Fargo & Company cut Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price target for the stock from $28.00 to $25.00 in a report on Monday, June 8th. HC Wainwright lifted their price objective on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Robert W. Baird lifted their target price on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Royal Bank Of Canada boosted their target price on Nurix Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.08.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 5,394 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the completion of the sale, the insider owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This represents a 4.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $624,027.20. This trade represents a 27.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 25,051 shares of company stock valued at $434,466. 6.70% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.